Skip to main content
Premium Trial:

Request an Annual Quote

Strand Life Sciences to Perform In Silico Research for Elan Pharmaceuticals

NEW YORK, Sept. 29 (GenomeWeb News) - Strand Life Sciences will perform in silico drug discovery research for Elan Pharmaceuticals, the Bangalore-based company said today.


As part of the collaboration, Strand will use its predictive modeling for efficacy and ADMET, custom library design, QSAR and pharmacophore modeling, structure-basead drug design, and data and visual mining technologies, as well as provide consulting.


Earlier this month, Strand Genomics changed its name to Strand Life Sciences. Elan Pharmaceuticals is a subsidiary of Elan, a neuroscience biotechnology company based in Dublinwith 2000 employees worldwide.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.